In UBUC (Table 4), 43 patients (29.1%) with high EFEMP1-expressing tumors experienced cancer deaths and 60 patients (40.5%) had subsequent metastatic tumors, whereas only 16 patients (10.9%) with low EFEMP1-expressing tumors had caner metastasis and nine patients (6.2%) died of the disease. This evidence concerns the gene EFEMP1 and metastatic neoplasm.